The stock climbed 20 per cent to settle at Rs 279.65 on BSE, its highest in the day.
On NSE, it rose 19.98 per cent to end at Rs 278.60.
On the volume front, 2.71 lakh shares of the company were traded on BSE and over 8.5 lakh shares changed hands at NSE during the day.
"The company is in-licensing two research-based products to be launched in the Indian cosmetic market this July," RPG Life Sciences said in a statement.
"Their (Labo Cosprophar) products have presence in over 33 countries, including Europe, the UK, the US and Asia. We are confident that both these products will be ideal to fill the need gap in respective therapies," RPG Life Sciences Managing Director C T Renganathan said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
